Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -261.73% is 194% below its 5-year average of -89.17%, around the middle of its 5-year range (-403.13%–-17.38%).
As of the fiscal period ended Tuesday, June 30, 2026. 26.45% below its 12-month average of -206.98%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -261.73%.
RETURN ON EQUITY (ROE)
-261.73%
RETURN ON EQUITY (ROE) AVG TTM
-206.98%
RETURN ON EQUITY (ROE) AVG 3Y
-191.61%
RETURN ON EQUITY (ROE) AVG 5Y
-89.17%
RETURN ON EQUITY (ROE) AVG 10Y
-72.20%
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-26.45%
CURRENT VS 3Y AVG
-36.60%
CURRENT VS 5Y AVG
-193.51%
CURRENT VS 10Y AVG
-262.53%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-38.57%
median of 563 covered companies
CURRENT VS SECTOR MEDIAN
-578.59%
vs the sector median at left
Moleculin Biotech, Inc.
Market Cap
$2.47M
Return on Equity (ROE)
-261.73%
TTM Avg
-206.98%
3Y Avg
-191.61%
5Y Avg
-89.17%
Market Cap
$2.53M
Return on Equity (ROE)
-391.26%
TTM Avg
-355.49%
3Y Avg
-474.62%
5Y Avg
-295.97%
Market Cap
$2.56M
Return on Equity (ROE)
N/A
TTM Avg
-419.35%
3Y Avg
-396.40%
5Y Avg
-293.00%
Market Cap
$2.36M
Return on Equity (ROE)
-1160.10%
TTM Avg
-528.10%
3Y Avg
-389.86%
5Y Avg
-336.02%
Market Cap
$2.33M
Return on Equity (ROE)
-69.79%
TTM Avg
-83.20%
3Y Avg
-70.37%
5Y Avg
-0.36%
Market Cap
$2.64M
Return on Equity (ROE)
-402.92%
TTM Avg
-276.14%
3Y Avg
-197.40%
5Y Avg
-116.89%
Market Cap
$2.28M
Return on Equity (ROE)
-75.70%
TTM Avg
-349.85%
3Y Avg
-22.96%
5Y Avg
-60.31%
Market Cap
$2.65M
Return on Equity (ROE)
-554.01%
TTM Avg
-109.66%
3Y Avg
1542.76%
5Y Avg
920.25%
Market Cap
$2.67M
Return on Equity (ROE)
-657.69%
TTM Avg
-358.53%
3Y Avg
-220.37%
5Y Avg
-149.08%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Moleculin Biotech, Inc. (MBRX) | $2.47M | -261.73% | -206.98% | -191.61% | -89.17% |
| FibroBiologics, Inc. Common Stock (FBLG)vs › | $2.53M | -391.26% | -355.49% | -474.62% | -295.97% |
| Nuwellis, Inc. (NUWE)vs › | $2.56M | N/A | -419.35% | -396.40% | -293.00% |
| GeoVax Labs, Inc. (GOVX)vs › | $2.36M | -1160.10% | -528.10% | -389.86% | -336.02% |
| Creative Medical Technology Holdings, Inc. (CELZ)vs › | $2.33M | -69.79% | -83.20% | -70.37% | -0.36% |
| bioAffinity Technologies, Inc. (BIAF)vs › | $2.64M | -402.92% | -276.14% | -197.40% | -116.89% |
| Onconetix, Inc. (ONCO)vs › | $2.28M | -75.70% | -349.85% | -22.96% | -60.31% |
| Jaguar Health, Inc. (JAGX)vs › | $2.65M | -554.01% | -109.66% | 1542.76% | 920.25% |
| iSpecimen Inc. (ISPC)vs › | $2.67M | -657.69% | -358.53% | -220.37% | -149.08% |
| Adagio Medical Holdings, Inc. (ADGM)vs › | $2.95M | N/A | -236.13% | -104.67% | -48.54% |
ROE
-261.7%
ROA
-143.8%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -261.73% |
| 2026-03-31 | -199.78% |
| 2025-12-31 | -159.42% |
| 2024-12-31 | -363.99% |
| 2024-09-30 | -403.13% |
| 2024-06-30 | -142.15% |
| 2024-03-31 | -124.26% |
| 2023-12-31 | -114.18% |
| 2023-09-30 | -74.76% |
| 2023-06-30 | -72.69% |
| 2023-03-31 | -65.83% |
| 2022-12-31 | -55.61% |
| 2022-09-30 | -42.93% |
| 2022-06-30 | -31.42% |
| 2022-03-31 | -25.20% |
| 2021-12-31 | -20.12% |
| 2021-09-30 | -19.33% |
| 2021-06-30 | -17.38% |
| 2021-03-31 | -23.26% |
| 2020-12-31 | -97.72% |
| 2020-09-30 | -127.97% |
| 2020-06-30 | -123.25% |
| 2020-03-31 | -67.83% |
| 2019-12-31 | -84.80% |
| 2019-09-30 | -64.25% |
| 2019-06-30 | -45.65% |
| 2019-03-31 | -95.28% |
| 2018-12-31 | -83.20% |
| 2018-09-30 | -82.01% |
| 2018-06-30 | -78.24% |
| 2018-03-31 | -55.43% |
| 2017-12-31 | -57.27% |
| 2017-09-30 | -43.12% |
| 2017-06-30 | -34.30% |
| 2017-03-31 | -25.90% |
| 2016-12-31 | -27.96% |
